Publique en esta revista
Información de la revista
Vol. 2. Núm. S2.
IV Simposio de Artritis Reumatoide
Páginas S42-S44 (Marzo 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. S2.
IV Simposio de Artritis Reumatoide
Páginas S42-S44 (Marzo 2006)
Artritis reumatoide: temas de debate
Acceso a texto completo
Razones contra el uso de antiinflamatorios no esteroideos durante la inducción de remisión de la artritis reumatoide
Visitas
...
Eliseo Pascual Gómeza,b,??
Autor para correspondencia
epascual@coma.es

Correspondencia: Dr. E. Pascual Gómez. Sección de Reumatología. Hospital General Universitario de Alicante. C/Maestro Alonso, 109. 08010 Alicante. España.
, Teresa Pedraz Penalvaa
a Sección de Reumatología. Hospital General Universitario de Alicante. Alicante. España
b Cátedra de Medicina (Reumatología). Universidad Miguel Hernández. Elche. Alicante. España
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.P. Symmons.
Looking back: rheumatoid arthritis-aetiology, occurrence and mortality.
Rheumatology (Oxford), 44 (2005), pp. 14-17
[2.]
P.J. Nicola, C.S. Crowson, H. Maradit-Kremers, K.V. Ballman, V.L. Roger, S.J. Jacobsen, et al.
Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis.
Arthritis Rheum, 54 (2006), pp. 60-67
[3.]
E.T. Molenaar, A.E. Voskuyl, H.J. Dinant, P.D. Bezemer, M. Boers, B.A. Dijkmans.
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.
Arthritis Rheum, 50 (2004), pp. 36-42
[4.]
J.S. Smolen, D.M. Van Der Heijde, E.W. St Clair, P. Emery, J.M. Bathon, E. Keystone, et al.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Arthritis Rheum, 54 (2006), pp. 702-710
[5.]
D.J. McCarty.
Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians.
J Rheumatol, 17 (1990), pp. 1115-1118
[6.]
G.F. Ferraccioli, G. Valentini, G. Valesini, S. Bombardieri.
Reconstructing the pyramid in rheumatoid arthritis. An urgent need.
Clin Exp Rheumatol, 19 (2001), pp. 621-624
[7.]
A. Van der Heide, J. Jacobs, J. Bijlsma.
The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomised controlled trial.
Ann Intern Med, 124 (1996), pp. 699
[8.]
M.A. Quinn, P. Emery.
Potencial for altering rheumatoid artritis outcome.
Rheum Dis Clin North Am, 31 (2005), pp. 763-772
[9.]
C. Book, T. Saxne, L.T. Jacobsson.
Prediction of mortality in rheumatoid arthritis based on disease activity markers.
J Rheumatol, 32 (2005), pp. 430-434
[10.]
L.T. Jacobsson, C. Turesson, A. Gulfe, M.C. Kapetanovic, I.F. Petersson, T. Saxne, et al.
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
J Rhaumatol, 32 (2005), pp. 1213-1218
[11.]
E. Batlle-Gualda.
Evaluación objetiva del enfermo en la práctica clínica.
Rev Esp Reumatol, 29 (2002), pp. 78-81
[12.]
P.T. Dawes, P.D. Fowler, S. Clarke, J. Fisher, A. Lawton, M.F. Shadforth.
Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression.
Br J Rheumatol, 25 (1986), pp. 44-49
[13.]
S.J. Alexander.
Clinical experience with naproxen inrheumatoid arthritis.
Arch Intern Med, 135 (1975), pp. 1429-1435
[14.]
B.L. Hazleman, P.P. Thomas.
Single-blind comparative study of nabumetone versus naproxen in the treatment of rheumatoid arthritis.
Am J Med, 30 (1987), pp. 60-64
[15.]
Z. Balogh, S.N. Papazoglou, M. MacLeod, W.W. Buchanan.
A crossover clinical trial of piroxicam, indomethacin and ibuprofen in rheumatoid arthritis.
Curr Med Res Opin, 6 (1979), pp. 148-153
[16.]
Z. Domljan, T. Durrigl.
Double-blind crossover comparison of piroxicam and indomethacin in rheumatoid arthritis.
Eur J Rheum Inflam, 6 (1983), pp. 291-296
[17.]
R.F. Willkens, P. Vreede.
Sodium meclofenamate (“Meclomen”) in the treatment of rheumatoid arthritis: a double- blind comparison with aspirin and placebo.
Pharmatherapeutica, 2 (1981), pp. 587-596
[18.]
E.M. Lemmel, W. Bolten, R. Burgos-Vargas, P. Platt, M. Nissila, D. Sahlberg, et al.
Efficacy and safety of meloxicam in patients with rheumatoid arthritis.
J Rheumatol, 24 (1997), pp. 282-290
[19.]
P.P. Geusens, K. Truitt, P. Sfikakis, P.L. Zhao, L. DeTora, S. Shingo, et al.
A placebo and active comparator- controlled trial of rofecoxib for the treatment of rheumatoid artritis.
Scand J Rheumatol, 31 (2002), pp. 230-238
[20.]
E. Collantes, S.P. Curtis, K.W. Lee, N. Casas, T. McCarthy, A. Melian, et al.
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
BMC Family Practice, 3 (2002), pp. 10-20
[21.]
S.Z. Zhao, J.L. Fiechtner, E.A. Tindall, S.D. Dedhiya, W.W. Zhao, J.T. Osterhaus, et al.
Evaluation of health- related quality of life of rheumatoid arthritis patients treated with celecoxib.
Arthritis Care and Research, 13 (2000), pp. 112-121
[22.]
K. Pavelka, P. Recher, K.M. Verburg.
Valdecoxib is as effective as diclofenac in the management of rheumatoid artritis with a lower incidente of gastroduodenal ulcers: results of a 26-week trial.
Rheumatology, 42 (2003), pp. 1207-1215
[23.]
B. Crowley, J.J. Hamill, S. Lyndon, J.F. McKellican, P. Williams, A.J. Miller.
Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid artritis: a comparative controlled clinical trial.
Curr Med Res Opin, 12 (1990), pp. 143-151
[24.]
H. Berry, B. Bloom, L. Fernandez, M. Morris.
Comparison of timegadine and naproxen in rheumatoid artritis. A placebo controlled trial.
Clin Rheumatol, 2 (1983), pp. 357-361
[25.]
E. Grace, A. Mewa, P.J. Rooney, W.W. Buchanan.
Clinical therapeutic trial of sodium meclofenamate and naproxen in rheumatoid artritis, with comments on the use of placebos in clinical trials.
Curr Med Res Opin, 8 (1983), pp. 417-424
[26.]
D.E. Bowers, H.R. Dyer, W.M. Fosdick, K.E. Keller, A.L. Rosenberg, P. Sussman, et al.
Naproxen in rheumatoid arthritis. A controlled trial.
Ann Intern Med, 83 (1975), pp. 470-475
[27.]
D.L.G. Howard.
A double-blind crossover evaluation of ketoprofen and placebo in rheumatoid arthritis with assessment of long-term tolerante.
J Int Med Res, 6 (1978), pp. 300-305
[28.]
J.R. Hannequin.
Efficacy of arthrotec in the treatment of rheumatoid artritis.
Scand J Rheumatol, 96 (1992), pp. S7-S14
[29.]
T.G. Osborn, R.L. Parks, T.L. Moore, M.W. Grisanti, G. Nesher, B.A. Caciolo.
Diflunisal versus naproxen in the management of rheumatoid artritis.
Clin Ther, 11 (1989), pp. 736-743
[30.]
R.M. Bennett.
A 12-week, double- blind, multicenter study comparing diflunisal twice daily and ibuprofen tour times daily in the treatment of rheumatoid artritis.
Clin Ther, 9 (1986), pp. S27-S36
[31.]
G. Katona, R. Burgos.
Double-blind crossover study to evaluate the efficacy of a single daily dose of naproxen in rheumatoid artritis.
Eur J Rheum Inflam, 6 (1983), pp. 233-241
[32.]
S.S. Bedi.
Double- blind comparison of alclofenac and aspirin in the treatment of rheumatoid artritis.
Curr Med Res Opin, 3 (1975), pp. 309-320
Copyright © 2006. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?